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Visualizing a Correlation between siRNA
Localization, Cellular Uptake,
and RNAi in Living Cells
Due to the broad potential applications of RNAi in
biology and medicine, it is important to understand the
mechanism of RNAi and to develop new approaches for
successful delivery of siRNA to target cells. A number
of approaches for delivering siRNA have recently been
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Worcester, Massachusetts 01605 explored. One approach is to deliver DNA or RNA tem-
plates encoding siRNA sequences to cells that can be
transcribed to express siRNA (reviewed in [8]). These
DNA- and RNA-based methods of siRNA expressionSummary
rely on plasmid or viral vectors for delivery and require
transfection, stable vector integration, and selection forRNA interference (RNAi) is the process by which short-
interfering RNA (siRNA) target a specific mRNA for deg- maintenance of expression through generations [8–16].
Other successful methods focus on the direct deliveryradation through interactions with an RNA-induced
silencing complex (RISC). Here, a clear correlation be- of siRNA into cells, and fidelity in cellular uptake of
siRNA is the key to causing RNAi using this type oftween siRNA localization, cellular uptake, and RNAi
activity was discovered by delivering siRNA into cells approach. Currently, the most often used method of siRNA
delivery is Lipofectamine transfection; however, the useusing siRNA-TAT47-57 peptide, siRNA-TAT47-57-derived
oligocarbamate conjugates, or nanoparticles. For suc- of this approach is limited to specific cell types, and
this procedure could be toxic to cells and animals [17].cessful RNAi, the localization of siRNA was distinctly
perinuclear, suggesting that siRNA is targeted to these Here, we describe the development of new strategies
for functional siRNA delivery to cells using cell-perme-regions for interactions with RISC to induce RNAi.
siRNA sequence variation and the presence of the able peptides, unnatural biopolymers, and nanopar-
ticles. We planned to explore siRNA delivery by the usetarget mRNA apparently did not change the subcellular
localization pattern of siRNA. Intriguingly, siRNA con- of protein transduction domains (PTDs) that facilitate the
uptake of proteins (reviewed in [18–22]). HIV-1-encodedjugated to TAT47-57 peptide or TAT47-57-derived oligocar-
bamate resulted in efficient RNAi activity and perinu- Tat, which is required for transcriptional transactivation
of the HIV-1 genome during transcription elongation,clear localization of siRNA that was distinctly different
from nonconjugated free TAT peptide nucleolar local- contains a PTD that efficiently promotes Tat cellular
uptake (reviewed in [23]). Tat protein is rapidly taken upization. These results suggest that interactions with
RISC dictate siRNA localization even when siRNA is by a broad spectrum of cell types and localizes to the
nucleus [24–27]. Cellular uptake of Tat depends on anconjugated to TAT47-57 peptide.
11 amino acid cationic peptide sequence that corre-
sponds to aa 47–57 (YGRKKRRQRRR) within Tat [28–31]Introduction
and confers a net positive charge to the peptide under
physiological conditions. TAT peptide conjugates pro-RNA interference (RNAi) is a process in which activation
of an intracellular pathway modulated by small-interfer- mote cellular uptake through endocytosis [32–36] and
facilitate the entry of macromolecules, including DNA,ing RNA (siRNA) composed of 21–23 nucleotides (nt)
leads to degradation of a specific, targeted mRNA (re- lipids, and antisense RNA, into many types of cells in
culture [28, 30, 37–44]. Therefore, we reasoned thatviewed in [1, 2]). To invoke RNAi-mediated gene silenc-
ing in human cells, duplex siRNA is transfected into siRNA-TAT peptide conjugates should lead to effective
and functional siRNA delivery, and this approach cancells. Once inside cells, siRNA duplexes undergo 5
phosphorylation, are unwound, and associate with the be used to specifically silence gene expression of target
proteins.RNA-induced silencing complex (RISC) [3–5]. Activated
RISC (RISC*) and the unwound antisense strand com- In this report, we show that functional siRNA can be
delivered into cells by using siRNA-TAT peptide, siRNA-plementary to the targeted mRNA interact with the
mRNA target. Single site-specific cleavage of the mRNA TAT-derived oligocarbamate conjugates, or nanopar-
ticles, and these siRNA are localized to specific cyto-target then occurs, with the position defined with refer-
ence to the 5 end of the siRNA antisense strand [3, 6]. plasmic compartments in the perinuclear region. We
observed a strong correlation between siRNA cellularOnce cleavage has occurred, target mRNA is degraded
and RISC is recycled for another cleavage reaction [7]. uptake, RNAi activity, and siRNA localization.
Because of its effectiveness in silencing specifically tar-
geted genes, RNAi is a mechanism that is being ex-
Resultsploited for a variety of laboratory applications and future
clinical therapeutics.
siRNA-TAT Peptide Conjugates Effectively Deliver
siRNA to Cells for Specific Gene Silencing
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siRNA, RNAi function, and siRNA localization. mRNA HeLa cells. The ratio of EGFP/RFP fluorescence in the
presence of siRNA was calculated and normalized to thetargets were either episomally expressed enhanced
green fluorescent protein (EGFP) or endogenous CDK9, EGFP/RFP ratio of mock-treated cells. Cells transfected
with unconjugated EGFP siRNA using Lipofectaminethe cyclin-dependent kinase subunit of positive tran-
scription elongation factor P-TEFb. Both siRNA se- showed 87% gene silencing activity. SS/AS-3TAT47-57
EGFP siRNA showed RNAi activity that could be directlyquences have been used previously to successfully knock-
down EGFP and CDK9 expression [5, 45, 46]. Structures correlated with increasing concentrations of the siRNA-
TAT peptide conjugate used in the experiments (Figureof the chemical modifications and siRNAs used in this
study are illustrated in Figure 1. 2B; lanes 6–10). We observed a quantitative gene silenc-
ing activity of70% when SS/AS-3TAT47-57 EGFP siRNAFirst, siRNA conjugated to TAT peptides were evalu-
ated for siRNA uptake efficiency and resulting RNAi ac- (200 and 300 nM) were used, demonstrating that SS/
AS-3TAT47-57 EGFP siRNA was functional after beingtivity. siRNA-TAT peptide conjugates were created by
annealing 21 nt 5 Cy3-labeled EGFP or CDK9 sense delivered into cells. Cells treated with 300 nM unconju-
gated SS/AS-3N3 EGFP siRNA plus free TAT47-57 peptidestrand siRNA to 3-N3 modified antisense strand siRNA
(see Experimental Procedures for details). Briefly, du- (lane 3) or SS/AS-3HBFC EGFP siRNA (lane 5) showed
no RNAi activity.plex siRNA with 3-N3 modification were incubated with
a heterobifunctional crosslinker (HBFC), sulfosuccinimi- Can we silence cellular genes by using siRNA cova-
lently linked with TAT peptide? To address this question,dyl 4-(p-maleimidophenyl)-butyrate. During this step,
the NHS ester group of the crosslinker reacted with the we prepared TAT peptide siRNA conjugates to target
CDK9, the cyclin-dependent kinase subunit of positiveprimary amino group at the 3 termini of the siRNA.
Maleimide-activated siRNA were then purified using a transcription elongation factor P-TEFb [46]. As shown
by Western blot analysis in Figure 3, SS/AS-3-TAT con-reverse-phase column and were incubated with an equal
molar ratio of TAT47-57 peptide or TAT47-57-derived oligo- jugate was able to effectively silence the expression of
CDK9 (54% and 82%, lanes 6 and 7, respectively)carbamate. A cysteine residue added to the amino termi-
nus of TAT47-57 peptide or TAT47-57-derived oligocarba- without effecting the expression of human cyclinT1 pro-
tein. Unconjugated SS/AS-3N3 CDK9 siRNA and freemate was used for siRNA conjugation, during which
the maleimide group of the crosslinker reacted with the TAT peptide (Figure 3; lane 1) or SS/AS-3HBFC CDK9
siRNA (Figure 3; lane 2) showed protein levels compara-sulfhydryl group of the cysteine residue of the peptide.
RNA-TAT47-57 peptide conjugation was analyzed by 20% ble to mock-treated cells (no siRNA). As observed for
EGFP silencing in the dual fluorescence assay, RNAinondenaturing polyacrylamide gel electrophoresis. siRNA
with TAT47-57 peptide conjugation showed retarded mo- activity increased by treating cells with increasing
amounts of SS/AS-3TAT47-57 CDK9 siRNA (Figure 3;bility when compared to unmodified duplex siRNA (data
not shown). siRNA-TAT conjugates were purified by de- lanes 3–7). These observations were consistent with the
above correlation between siRNA cellular uptake andnaturing gels or reverse phase HPLC.
Cells transfected with Cy3-SS/AS-3TAT47-57 EGFP RNAi activity, with CDK9 siRNA depending on conju-
gated TAT47-57 for uptake and resulting RNAi activity.siRNA were tested at different concentrations for siRNA
cellular uptake by measuring Cy3 fluorescence at 6 or Altogether, these results demonstrate that siRNA cova-
lently modified with TAT47-57 can be effectively delivered16 hr posttransfection. The measured fluorescence was
then normalized to cells transfected with Cy3-SS/AS- to cells and these siRNA-TAT conjugates successfully
enter the RNAi pathway in cells to silence specific gene3TAT47-57 EGFP siRNA using Lipofectamine. Cells trans-
fected with the TAT peptide fused to siRNA exhibited expression.
efficient siRNA cellular uptake that was enhanced by
increasing both the amount of Cy3-SS/AS-3TAT47-57
Unnatural TAT-Derived Biopolymer ConjugatedEGFP siRNA used per transfection and time post-
to siRNA Deliver siRNA to Cells for RNAitransfection (Figure 2A; lanes 7 and 8 compared to lanes
To increase the stability of siRNA-TAT peptides and to5 and 6). The uptake of 150–300 nM Cy3-SS/AS-
test the possibility of attaching unnatural structures to3TAT47-57 EGFP siRNA after16 hr (lane 7 and 8) was
create functional siRNA, we synthesized a TAT-derivedalmost equal to uptake observed using 20g of Lipofec-
oligocarbamate and conjugated to siRNA sequencestamine and 150 nM Cy3-SS/AS-3N3 unconjugated
(Figure 1). The oligocarbamate backbone consists of aEGFP siRNA (lane 1). Cells transfected with unconju-
chiral ethylene backbone linked through relatively rigidgated Cy3-SS/AS-3N3 EGFP siRNA plus free TAT47-57
carbamate groups [47]. This modified TAT oligocarba-peptide or Cy3-SS/AS-3HBFC siRNAs harboring only
mate was previously shown to function similarly to wild-the HBFC linker without conjugated TAT47-57 did not show
type TAT peptides in TAR RNA binding experimentssignificantly measurable uptake of siRNA (lanes 2 and 4),
and was resistant to proteinase K digestion [48]. Afterdemonstrating that siRNA uptake did not occur without
synthesis and purification, oligocarbamate was attachedconjugated TAT47-57. These results indicated that siRNA
to the siRNA using methods described above for TAT-can be effectively delivered to cells by covalently modi-
siRNA conjugate preparation. Cy3-SS/AS-3TAT47-57 (car-fying with TAT peptides.
bamate) EGFP siRNA constructs were evaluated forTo quantitatively determine the gene silencing func-
siRNA cellular uptake and associated RNAi activity. Cel-tion of TAT-conjugated siRNA sequences, we used a
lular uptake of Cy3-SS/AS-3TAT47-57 (carbamate) EGFPdual fluorescence assay [5]. In this assay, SS/AS-
siRNA was concentration and time dependent as ob-3TAT47-57 EGFP siRNA and plasmids harboring EGFP
and red fluorescent protein (RFP) were transfected into served with TAT-siRNA conjugates (Figures 2A and 2B).
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Figure 1. Structures of Chemical Modifications and siRNA
(A) Structure and nomenclature of chemical modifications.
(B) Classification and nomenclature of the modified EGFP siRNAs. Sense (top row, purple) and antisense (bottom row, black) strands of siRNA
species are shown with their 5-Cy3 and 3-N3, 3-HBFC, or 3-TAT47-57 modifications.
(C) Classification and nomenclature of the modified CDK9 siRNAs. Sense (top row, cyan) and antisense (bottom row, blue) strands of siRNA
species are shown with their 5-Cy3 and 3-N3, 3-HBFC, 3-TAT47-57, or 3-TAT47-57 (carbamate) modifications. siRNA constructs contained
biotin linked to the 3 end of the sense strand.
Maximum (67%) siRNA uptake was observed when cells significant siRNA uptake (Figure 2A; lane 3), indicating
that Cy3-SS/AS-3TAT47-57 (carbamate) EGFP siRNA up-were treated for 16 hr with 300 nM siRNA (Figure 2A;
lane 12). Unconjugated Cy3-SS/AS-3N3 EGFP siRNA take depended on the covalent attachment of the carba-
mate with the siRNA. These results show that the oligo-transfected with free TAT47-57 (carbamate) did not show
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Figure 3. Silencing of Endogenous Gene Expression by siRNA Con-
jugated to TAT47-57 Peptide
CDK9 duplex siRNAs with 3-amino modification at antisense strand
(SS/AS-3N3) were conjugated with TAT47-57 peptide and directly
added into the medium (lanes 3–7). At 42 hr postincubation, protein
in 60 g of total cell lysate was subjected to Western blotting analy-
sis with antibodies against CDK9 (upper panel) and hCycT1 (lower
panel). Protein was resolved by 10% SDS-PAGE and transferred
onto a PVDF membrane that was probed with antibodies against
CDK9 (upper panel). For control experiments, the same membrane
was also probed with anti-hCycT1 antibody (lower panel). Protein
contents were visualized with BM Chemiluminescence Blotting Kit
followed by exposure to X-ray film (Kodak MR-1). For comparison,
CDK9 knockdown resulting from SS/AS-3N3 siRNA transfected
with Lipofectamine is shown in lane 8. Negative controls included
cells treated with 400 nM unconjugated SS/AS-3N3 CDK9 siRNA
plus free TAT47-57 peptide (lane 1), SS/AS-3HBFC CDK9 siRNA
(linker only without TAT47-57; lane 2), or mock-treated (no siRNA) cells
(lane 9).
Figure 2. siRNA Cellular Uptake and Functional RNA Interference
Mediated by siRNA-TAT47-57 Peptide or siRNA-TAT47-57-Derived Oli-
gocarbamate Conjugates
carbamate modification of siRNA promotes cellular uptake
(A) Uptake of siRNA by HeLa cells through TAT peptide- or TAT-
of siRNA.derived oligocarbamate-mediated delivery. Various amounts of Cy3-
Next, we tested the gene silencing function of SS/SS/AS-3TAT47-57 (lanes 5–8) or Cy3-SS/AS-3TAT47-57 (carbamate)
AS-3TAT47-57 (carbamate) conjugates to silence EGFPEGFP siRNA (lanes 9–12) were added to media and cells were cul-
tured in the mixture for 6 or 16 hr. Fluorescence intensity of Cy3, expression in our dual fluorescence assay or CDK9
which acted as an indicator of uptake efficiency, was measured as knockdown. Lipofectamine transfection with SS/AS-
described in Experimental Procedures and normalized to the signal 3N3 EGFP siRNA resulted in 83% RNAi activity while the
from cells transfected using 20 g Lipofectamine and 300 nM Cy3-
maximum RNAi activity observed for SS/AS-3TAT47-57SS/AS-3N3 EGFP siRNAs (lane 1). The mixture of unconjugated
(carbamate) EGFP siRNA (300 nM) was 33% (Figure 2B;Cy3-SS/AS-3N3 EGFP siRNA plus free TAT47-57 peptide (300 nM, 16
hr; lane 2), unconjugated Cy3-SS/AS-3N3 EGFP siRNA plus free
TAT47-57 (carbamate) (300 nM, 16 hr; lane 3), and Cy3-SS/AS-3HBFC
(300 nM, 16 hr; lane 4) showed no uptake in HeLa cells. Cellular
uptake efficiency that varied with concentration was observed: lane (RFP) fluorophore was determined in the presence of siRNA and
5: Cy3-SS/AS-3TAT47-57 EGFP siRNA (150 nM, 6 hr); lane 6: Cy3- was normalized to the ratio observed in the absence of siRNA (mock,
SS/AS-3TAT47-57 EGFP siRNA (300 nM, 6 hr); lane 7: Cy3-SS/AS- lane 1). Normalized ratios1 indicate specific RNA interference. The
3TAT47-57 EGFP siRNA (150 nM, 16 hr); lane 8: Cy3-SS/AS-3TAT47-57 RNAi activity of EGFP siRNA transfected by Lipofectamine acted as
EGFP siRNA (300 nM, 16 hr); lane 9: Cy3-SS/AS-3TAT47-57 (carba- a positive control (150 nM siRNA; lane 2). Negative controls included
mate) EGFP siRNA (150 nM, 6 hr); lane 10: Cy3-SS/AS-3TAT47-57 cells treated with mixtures of unconjugated Cy3-SS/AS-3N3 siRNA
(carbamate) EGFP siRNA (300 nM, 6 hr); lane 11: Cy3-SS/AS- plus free TAT47-57 peptide (300 nM; lane 3), unconjugated Cy3-SS/
3TAT47-57 (carbamate) EGFP siRNA (150 nM, 16 hr); and lane 12: AS-3N3 siRNA plus free TAT47-57 (carbamate) (300 nM; lane 4) or
Cy3-SS/AS-3TAT47-57 (carbamate) EGFP siRNA (300 nM, 16 hr). Cy3-SS/AS-3HBFC (linker only without TAT47-57; 300 nM; lane 5),
(B) Quantitative analysis of RNAi effect by siRNA conjugated with which did not show uptake in HeLa cells. RNAi activity that varied
unmodified TAT47-57 peptide or TAT47-57 (carbamate). Various amounts with concentration was observed. Lane 6: Cy3-SS/AS-3TAT47-57
of Cy3-SS/AS-3TAT47-57 EGFP siRNA (25–300 nM, lanes 6–10) or EGFP siRNA (25 nM); lane 7: Cy3-SS/AS-3TAT47-57 EGFP siRNA
Cy3-SS/AS-3TAT47-57 (carbamate) EGFP siRNA (lanes 11–15) were (50 nM); lane 8: Cy3-SS/AS-3TAT47-57 EGFP siRNA (100 nM); lane
added to media and cells were cultured in the mixture for 6 hr or 9: Cy3-SS/AS-3TAT47-57 EGFP siRNA (200 nM); lane 10: Cy3-SS/
16 hr. At 16 hr postincubation, cells were washed 3 with PBS to AS-3TAT47-57 (carbamate) EGFP siRNA (300 nM); lane 11: Cy3-
remove the siRNA containing mixture. pEGFP-C1 and pDsRed2-N1 SS/AS-3TAT47-57 (carbamate) EGFP siRNA (25 nM); lane 12:
reporter plasmids were then cotransfected into HeLa cells. At 42 hr Cy3-SS/AS-3TAT47-57 (carbamate) EGFP siRNA (50 nM); lane 13:
posttransfection, clear lysate was prepared and subjected to dual Cy3-SS/AS-3TAT47-57 (carbamate) EGFP siRNA (100 nM); lane 14:
fluorescence assay analysis as described in Experimental Proce- Cy3-SS/AS-3TAT47-57 (carbamate) EGFP siRNA (200 nM); and lane
dures. The fluorescence intensity ratio of target (EGFP) to control 15: Cy3-SS/AS-3TAT47-57 (carbamate) EGFP siRNA (300 nM).
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lane 15). The lower RNAi activity observed with SS/AS-
3TAT47-57 (carbamate) EGFP siRNA as compared to un-
modified SS/AS-3TAT47-57 EGFP siRNA was likely attrib-
uted to the lower siRNA uptake measured at the same
concentration (Figure 2A; lane 12). In support of this
conclusion, significant knockdown of CDK9 protein lev-
els was observed with SS/AS-3TAT47-57 (carbamate)
CDK9 siRNA at concentrations of 50–400 nM. Concen-
trations of 200 and 400 nM resulted in the highest level
of knockdown and significantly reduced CDK9 protein
expression (data not shown). Unconjugated SS/AS-3N3
EGFP siRNA plus free TAT47-57 (carbamate) showed pro-
tein levels comparable to mock-treated (no siRNA) cells
(data not shown), indicating that CDK9 knockdown de-
pended on siRNAs conjugated to TAT47-57-derived oli-
gocarbamate for delivery. Collectively, these results in-
dicated that the siRNA-TAT-derived oligocarbamate
conjugates were capable of being taken up by cells, and
subsequently, entered the RNAi pathway.
Nanoparticles Effectively Deliver Functional
siRNA to Cells
In addition to TAT47-57 peptide-siRNA conjugation strat-
egy, we tested nanoparticles to deliver functional siRNA
to cells. We used a generation four polyamidoamine
dendrimer that had 64 surface groups and a diameter
of 45 A˚ (reviewed in [49]). Here, we denote these particles
as NP-45. We transfected cells with Cy3-SS/AS-3N3
EGFP siRNA and NP-45 as described above. To evaluate
cellular uptake of siRNA, the fluorescence of Cy3-SS/
AS-3N3 EGFP siRNA using NP-45 was normalized to
the corresponding Cy3-SS/AS-3N3 EGFP siRNA fluo-
rescence in cells transfected with 20 g/ml of Lipofec-
tamine. As shown in Figure 4A, the efficiency of siRNA
uptake using 20–40 g/ml NP-45 (lanes 3 and 4) was
almost equal to that measured for 20 g/ml Lipofectam-
Figure 4. Delivery of siRNA Mediated by Nanoparticles, NP-45ine (lane 1). However, NP-45 concentrations above this
(A) 150 nM Cy3-SS/AS-3N3 EGFP siRNA was delivered into HeLarange lowered the siRNA uptake40%–60% (Figure 4A;
cells using NP-45 (10 g/ml to 1 mg/ml, lanes 2–8). At 6 hr post-lanes 5–8), suggesting that there was a critical concen-
transfection, Cy3-SS/AS-3N3 EGFP siRNA was isolated from cells
tration range for NP-45-siRNA delivery. Although the and subjected to fluorescence measurements as described in Ex-
total cellular uptake was not significantly changed at perimental Procedures. The fluorescence intensity of Cy3 was used
higher concentrations of NP-45, we observed a signifi- as an indicator of the uptake of Cy3-SS/AS-3N3 EGFP siRNA. For
control experiments, transfection mediated by 20g/ml Lipofectam-cant change in the cytoplasmic localization and distribu-
ine was performed (lane 1). Transfection efficiency was determinedtion of siRNA (see Figure 5 and section below).
by normalizing the Cy3 signal from cells treated with siRNA-NP-45RNAi activity associated with NP-45-mediated siRNA
to the signal derived from Lipofectamine-mediated transfection.
delivery was also determined by targeting endogenous (B) Silencing of CDK9 expression by NP-45-mediated delivery of
CDK9 mRNA. Cells transfected with SS/AS-3N3 CDK9 siRNA. 150 nM SS/AS-3N3 CDK9 siRNA was delivered into HeLa
siRNA using NP-45 (20–200 g/ml) showed varying de- cells using NP-45 (lanes 2–7). At 42 hr, proteins in 60 g of total cell
lysate were subjected to Western blotting analysis with antibodiesgrees of RNAi activity and the highest level of RNAi
against CDK9 (upper panel) and hCycT1 (lower panel), as describedactivity (91%) was observed with 40 g/ml NP-45 (Fig-
in Figure 2B. For control experiments, cells were treated with NP-ure 4B; lane 3). This maximal RNAi activity correlated
45 (40 g/ml) without siRNA (lane 1).
with the high siRNA uptake efficiency at the same NP-
45 concentration (Figure 4A, lane 4). RNAi efficiencies
were decreased (68%–42%) when 100–200 g/ml of comparable to mock-treated (no siRNA) cells (Figure
4B; compare lanes 6 and 7 with lane 1). These resultsNP-45 were used (Figure 4B, lanes 4 and 5). Higher
concentration of NP-45 lowered the cellular uptake were consistent with NP-45 being effective for both
siRNA uptake and RNAi activity only within a critical(40%–60%) but did not completely inhibit siRNA uptake
(Figure 4A, lanes 5–8), suggesting that fraction of active concentration range and further suggested that there
was a correlation between siRNA uptake and efficientpools of siRNA remained in cytoplasm at 100–200 g/ml
concentrations of NP-45 causing knockdown of CDK9 RNAi activity. These results demonstrate that nanopar-
ticles such as NP-45 could provide new useful approachexpression (Figure 4B, lanes 4 and 5). The RNAi activity
measured using 400 or 1000g/ml NP-45, however, was for effective and functional siRNA delivery.
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Figure 5. Localization of siRNA
HeLa cells were cultured in 35 mm dishes
with glass cover slip bottoms. Cy3-SS/AS-
3N3 EGFP siRNA was transfected alone (A),
cotransfected with the target reporter gene
(B) into HeLa cells by Lipofectamine (A and B),
and NP-45 (C and D). Cy3-SS/AS-3TAT47-57
EGFP siRNA (E) or TAT47-57-Rh (TAT47-57 conju-
gated only to rhodamine) (F) was added to
the medium of cultured HeLa cells. At 16 hr
posttreatment, cells were fixed in 100%
methanol at 20C for 10 min and then sub-
jected to DAPI staining. Localization of the
duplex siRNA was monitored by Leica con-
focal microscopy. Overlay images of siRNA
and nucleus (DAPI) and phase contrast image
are shown here. Localization of rhodamine-
labeled TAT47-57 peptide is shown in (F).
RNAi Activity Is Associated with siRNA The effect of NP-45 on the localization of Cy3-SS/AS-
3N3 EGFP siRNA was assessed after transfecting theLocalization to Specific Compartments
in the Cytoplasm Cy3-labeled siRNA and NP-45 (40 g/ml or 200 g/ml).
siRNA transfected with 40 g/ml NP-45 also localizedTo visualize siRNA in cells and to determine a correlation
between siRNA localization and function, we used Cy3- to perinuclear regions of the cytoplasm although it ap-
peared to aggregate to more discrete areas within thelabeled siRNA and delivered to HeLa cells by employing
various approaches described above. Cy3-SS/AS-3N3 perinuclear region (Figure 5C). Interestingly, using higher
concentration of NP-45 (200 g/ml), a shift in siRNAEGFP siRNA localization was first established using Li-
pofectamine, and transfections were performed with or localization patterns was observed with cytoplasmic lo-
calization appearing more diffuse (Figure 5D). In addi-without an EGFP reporter plasmid to determine whether
siRNA localization was affected in the presence and tion, siRNA was observed in both the nucleus and nucle-
olus (Figure 5D), indicating that delivering siRNA to cellsabsence of the mRNA target. Transfected cells, live or
stained with DAPI, were observed by confocal micros- using NP-45 at this higher concentration altered siRNA
subcellular localization. It was not clear how NP-45 atcopy, and Cy3-labeled siRNA localization was similar in
live and fixed cells. siRNA localized to the cytoplasm higher concentrations was altering normal siRNA sub-
cellular localization. However, these observations corre-around the periphery of the nucleus, and this pattern
was not altered by the presence of the EGFP reporter lated well to the lower RNAi activity associated with
using higher concentrations of NP-45 and suggestedconstruct (Figures 5A and 5B), indicating that siRNA
localization was perinuclear and did not change in the that subcellular localization of siRNA was important for
RNAi.presence of an mRNA target.
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Figure 6. Localization of CDK9 siRNA
(A) Structure and nomenclature of the modi-
fied CDK9 siRNAs for localization studies.
Sense (top row, cyan) and antisense (bottom
row, blue) strands of siRNA species are
shown with their 5-Cy3 modifications.
(B) HeLa cells were transfected with CDK9
WT (Cy3-SS/AS) siRNA (a) or CDK9 mm (Cy3-
SS/AS) siRNA (b) by lipofectamine as de-
scribed in Figure 5. At 16 hr posttreatment,
cells were fixed in 100% methanol at 20C
for 10 min and then subjected to DAPI stain-
ing. Localization of the duplex siRNA was
monitored by Leica confocal microscopy.
Overlay images of siRNA and nucleus (DAPI)
and DIC image are shown here.
Next, the affect of the TAT47-57 peptide conjugate on cells. As shown in Figure 6B, siRNA localized to the
cytoplasm around the periphery of the nucleus as ob-siRNA localization was analyzed in cells treated with
300 nM Cy3-SS/AS-3TAT47-57 EGFP siRNA. As shown in served in EGFP siRNA (Figure 5), indicating that siRNA
localization was sequence independent and endoge-Figure 5E, Cy3-SS/AS-3TAT47-57 EGFP siRNA subcellu-
lar localization was nearly identical to the perinuclear nous mRNA target did not change the localization pat-
tern. These results suggest that the initial steps of RNAilocalization seen with Cy3-SS/AS-3N3 EGFP siRNA
transfected using Lipofectamine. In addition, after com- pathway involving siRNA uptake and subcellular local-
ization are common for both functional and nonfunc-paring cells transfected with TAT47-57 conjugated only
to rhodamine (Figure 5F; TAT-Rh) with Cy3-SS/AS- tional siRNA sequences and the target mRNA cleavage
is decided at later stages by active RISC complexes.3TAT47-57 EGFP siRNA-tranfected cells, it was apparent
that siRNA dictated the localization of the Cy3-SS/AS- Finally, we compared the localization of unmodified
Cy3-SS/AS-3TAT47-57 and Cy3-SS/AS-3TAT47-57 (car-3TAT47-57 EGFP siRNA to perinuclear regions and did
not get targeted to the nucleolus where TAT47-57-Rh alone bamate) EGFP siRNAs. Localization of Cy3-SS/AS-
3TAT47-57 (carbamate) EGFP siRNAs exactly mirroredlocalized. This indicated that either the Cy3-SS/AS-
3TAT47-57 EGFP siRNA was sequestered by RISC in the that of unmodified Cy3-SS/AS-3TAT47-57 EGFP siRNAs
to the cytoplasm surrounding the nucleus (Figure 7).cytoplasm, precluding the conjugate from entering the
nucleus, or the siRNA was being cleaved from the TAT These observations demonstrated that TAT-derived oli-
gocarbamate effectively delivered siRNA into cells with-TAT47-57 peptide, permitting it to localize to perinuclear
regions in the cytoplasm. In either case, the observed out altering the perinuclear localization seen with the
other methods of delivery. This suggested that reducedlocalization was consistent with the high siRNA cellular
uptake and RNAi efficiencies of Cy3-SS/AS-3TAT47-57 RNAi activity associated with the Cy3-SS/AS-3TAT47-57
(carbamate) EGFP siRNA construct in the dual fluores-EGFP siRNA and provided a strong correlation between
siRNA subcellular localization and RNAi activity. cence assay was not due to defects in siRNA localiza-
tion, but was more likely related to cellular uptake ofIs the siRNA subcellular localization sequence spe-
cific? To address this question, we visualized localiza- the construct or the fidelity of siRNA function upon being
localized correctly.tion of siRNAs targeting CDK9 mRNA. Two siRNA se-
quences, wild-type and mismatch (Figure 6A), were
tested in localization experiments. Cy3-SS/AS wild-type Discussion
and mismatch siRNA localization was examined using
Lipofectamine, and transfections were performed as de- Visualizing siRNA in living cells and determining how
siRNA localization correlates to RNAi activity is essentialscribed above. Transfected cells, live or stained with
DAPI, were observed by confocal microscopy, and Cy3- for understanding the mechanism of RNAi. Our results
show that siRNAs were localized to perinuclear regionslabeled siRNA localization was similar in live and fixed
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Figure 7. Localization of siRNA Conjugated
with Cell-Penetrating TAT47-57 Peptide and
Carbamate in Living Cells
HeLa cells were cultured in 35 mm dishes
with glass coverslip bottoms. Cy3-SS/AS-
3TAT47-57 EGFP siRNA (A) or Cy3-SS/AS-
3TAT47-57 (carbamate) EGFP siRNA (B) was
added into the culture medium directly. At 16
hr postaddition of the conjugates, the Cy3
signal of the siRNA was monitored in living
cells by Leica confocal microscopy.
and this localization was correlated to RNAi efficiency. ciated with the functionality of the siRNA and not siRNA
localization. If siRNA needs to be cleaved from TAT47-57In addition, we developed new approaches to deliver
functional siRNA to cells. peptide to efficiently cause RNAi, RISC or some other
component of the RNAi pathway may act to monitorTo date, Lipofectamine transfection protocols have
been the standard approach for introducing siRNA into overall siRNA structure when siRNA enters into cells.
This monitoring of siRNA-conjugates then lead to modi-cells. Cells transfected with siRNA using Lipofectamine
exhibit high levels of siRNA cellular uptake, efficient fying siRNAs accordingly to maintain the fidelity of the
siRNA-RISC interactions required for RNAi. With carba-RNAi effects, and siRNA perinuclear localization, repre-
senting a collective criteria required for siRNA delivery mate structures introduced into the siRNA-conjugate
construct, the RNAi machinery may not efficiently recog-and subsequent gene silencing. Due to the toxicity and
certain cell-type specificity associated with Lipofectam- nize the siRNA conjugated to the peptide and/or cannot
efficiently cleave the peptide away from the siRNA, ac-ine, we planned to explore other approaches of siRNA
delivery that could result in high levels of RNAi activity. counting for the lower RNAi activity observed.
An important discovery arising from this analysis wasBoth nanoparticles and TAT peptide conjugates repre-
sent new siRNA delivery approaches that do not confer the specific perinuclear siRNA localization observed
with Lipofectamine, NP-45, and TAT47-57 peptide or car-toxic effects to cells and give rise to efficient RNAi activ-
ities. bamate conjugates. Previous studies reporting the pres-
ence of siRNA in cytoplasmic pools of fractionated cellsThe siRNA-TAT47-57 peptide conjugates did not alter
siRNA localization even when transfected at the highest [50], dicer localization to the cytoplasm [51], and restric-
tion of RNAi in human cells to the cytoplasm [52], furtherconcentration tested. There was also a distinct relation-
ship between the concentration of the conjugate trans- support our findings of perinuclear siRNA localization
in the cytoplasm. Our studies also showed that localiza-fected and siRNA uptake, with increasing concentra-
tions resulting in increased uptake and RNAi activity. tion to these perinuclear regions was an important factor
for efficient RNAi and suggested that RISC componentsBoth NP-45 and the TAT47-57 peptide conjugates showed
this correlation between siRNA uptake and efficient may also localize to these perinuclear regions, creating
a focal point for RNAi factories.RNAi. Analysis of the siRNA-TAT47-57 -derived oligocar-
bamate conjugate revealed that altering the peptide
backbone structure of the conjugate did not inhibit Significance
siRNA uptake and these modified siRNAs-TAT47-57 (car-
bamate) conjugates did not prevent the siRNA from en- RNA interference (RNAi) is the process by which
short-interfering RNA (siRNA) target a specific mRNAtering the RNAi pathway to cause moderate RNAi. The
moderate RNAi efficiency associated with these modi- for degradation through interactions with an RNA-
induced silencing complex (RISC). Because of its re-fied siRNA could be due to two reasons: (1) lower cellular
siRNA uptake, and (2) the stabilized and protease-resis- markable potential for use in a myriad of laboratory
and clinical applications, the mechanistic details oftant carbamate structure of TAT47-57 peptide affected
siRNA entry into the RNAi pathway. This raises the possi- RNAi need to be further defined and effective methods
for delivering siRNA to cells developed. Herein, a clearbility that siRNA was cleaved from unmodified TAT47-57
peptide when introduced into cells, allowing released correlation between siRNA localization, siRNA uptake
efficiency, and RNAi activity was discovered throughsiRNA to enter the RNAi pathway. Consistent with this
possibility is the finding that the siRNA localization pat- developing different approaches for delivering siRNA
into cells. Our studies established that for functionalterns of the unmodified and modified conjugates were
virtually identical (Figure 6), suggesting that RISC dic- RNAi, siRNA localization was distinctly perinuclear.
Localization to these perinuclear regions was alsotated siRNA localization instead of TAT47-57 peptide.
These results also suggested that the lower RNAi effi- highly correlative to RNAi efficacy, suggesting that
siRNA is targeted to these perinuclear regions for in-ciency observed with carbamate modification was asso-
Visualizing RNAi in Living Cells
1173
the mixture for 6–16 hr. Cells were then washed three times withteractions with RISC to cause RNAi. siRNA conjugated
PBS to remove the siRNA-containing medium. Total DNA, RNA, andto TAT47-57 peptide or TAT47-57-derived oligocarbamate
the 5 Cy3-labeled peptide-conjugated siRNAs were isolated fromresulted in efficient RNAi activity and siRNA perinu-
cells and were subjected to fluorescence measurements on a PTI
clear localization that was distinctly different from free (Photo Technology International) fluorescence spectrophotometer.
TAT47-57 peptide nucleolar localization, suggesting that The slits were set at 4 nm for both excitation and emission lights.
All experiments were carried out at room temperature. Cy3 fluores-interactions with RISC dictated siRNA localization in-
cence was detected by exciting at 550 nm and emission spectrumstead of TAT47-57 peptide. siRNA delivered to cells using
was recorded from 560 to 650 nm. The spectrum peak at 570 nmnanoparticles, NP-45, showed efficient cellular up-
represented the fluorescence intensity of Cy3 and was an indicatortake, RNAi activity, and perinuclear localization, but a
of 5 Cy3-labeled siRNA uptake. Standard Lipofectamine-mediated
critical concentration threshold of NP-45 dictated the transfections were performed as positive control experiments.
efficiency of siRNA uptake, RNAi activity, and siRNA
localization. Altogether, these studies provided insight Quantitative Analysis of RNAi Effects
of siRNA Conjugated with TAT Peptidesinto the relationship between siRNA cellular uptake,
SS/AS-3TAT47-57 or SS/AS-3TAT47-57 (carbamate) EGFP siRNA con-localization, and function, and led to the discovery of
jugates were directly added to the medium containing HeLa cellsseveral new and effective methods for siRNA delivery.
cultured in 6-well plates. For control experiments, unmodified
siRNAs were transfected by Lipofectamine. At 16 hr postincubation,
Experimental Procedures cells were washed three times with PBS to remove the siRNA-
containing medium. For the dual fluorescence assay, pEGFP-C1
siRNA Preparation (0.33 g) and DsRed2-N1 (0.66 g) reporter plasmids were cotrans-
21 nt siRNAs were chemically synthesized as 2 bis (acetoxyethoxy)- fected into HeLa cells using Lipofectamine (20 g/ml) in a 1 ml
methyl ether protected oligos by Dharmacon (Lafayette, CO). Syn- transfection reaction. EGFP-C1 encoded enhanced green fluores-
thetic Oligonucleotides were deprotected, annealed, and purified cence protein (EGFP) and DsRed2-N1 encoded red fluorescence
as described by the manufacturer. Successful duplex formation was protein (RFP) (Clontech). At 42 hr posttransfection, cells were lysed
confirmed by 20% nondenaturing polyacrylamide gel electrophore- in ice-cold reporter lysis buffer (Promega) and 300 g of total cell
sis. All siRNA were stored in DEPC-treated water at 80C. The lysate in 160 l reporter lysis buffer was subject to fluorescence
siRNA sequence targeting EGFP was from position 238–258 relative measurements using the PTI fluorescence spectrophotometer. Flu-
to the start codon [5]. For RNA interference targeting endogenous orescence of EGFP in the cell lysate was detected by exciting at
gene CDK9, the sequence of CDK9-specific siRNA duplexes was 478 nm and emission spectrum was recorded from 498 to 650 nm.
designed and subjected to a BLAST search against the human ge- The spectrum peak at 507 nm represents the fluorescence intensity
nome sequence to ensure only CDK9 gene was targeted. The siRNA of EGFP. Fluorescence of RFP in the same cell lysate was detected
sequence targeting CDK9 was from position 258-278 relative to the be exciting at 568 nm and emission spectrum was recorded from
start codon. Duplex siRNAs with 5 Cy3-modified sense strands 588 to 650 nm, and the spectrum peak at 583 nm represents the
were used to determine the uptake efficiency of siRNA while duplex fluorescence intensity of RFP. The fluorescence intensity ratio of
siRNAs with 3 amino modification were used in conjugating siRNA target (EGFP) to control (RFP) fluorophore was determined in the
with TAT peptide as described below. presence of siRNA and was normalized to that observed in the
absence of siRNA. Normalized ratios 1 indicated specific inter-
Conjugating siRNA with TAT47-57 Peptide ference.
TAT47-57 peptide with unmodified or oligocarbamate modified back-
bone (Cys-47Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg57; 47–57 Cellular Uptake of siRNA by Nanoparticles
amino acid sequence from wild-type TAT protein plus a cysteine HeLa cells were maintained at 37C in Dulbecco’s modified Eagles
residue, which provides the free sulfhydryl group) were synthesized medium (DMEM, Invitrogen) supplemented with 10% fetal bovine
by solid-phase synthesis as described previously [47]. Modified serum (FBS), 100 U/ml penicillin, and 100 g/ml streptomycin (In-
siRNAs containing a 3-amino group with a 3-carbon linker (3N3) vitrogen). Cells were regularly passaged at subconfluence and
were formed by annealing deprotected 3N3 modified single- plated on 60 mm plates 16 hr before transfection at 70% confluency.
stranded siRNA with its complementary strand sequences. 25 nmol 21 nt 5-Cy3-labeled EGFP sense strand siRNA was deprotected,
duplex siRNA with 3N3 modification were then incubated with 50- annealed to unmodified antisense strand siRNA, and purified as
fold molar excess of a heterobifinctional crosslinker (HBFC), sulfo- described above. As a control, Lipofectamine-mediated transfec-
succinimidyl 4-(p-maleimidophenyl)-butyrate, in 400l PBS reaction tions were performed as described by the manufacturer for adherent
buffer (20 mM sodium phosphate, 150 mM NaCl, pH 7.2). After cell lines. For siRNA delivery by nanoparticles, we used a generation
shaking for 1 hr at room temperature, the reaction products were four polyamidoamine dendrimer that had 64 surface groups and a
separated by a reverse-phase column. The fractions containing the diameter of 45 A˚. Here, we denote these particles as NP-45. We
activated siRNA-crosslinker were pooled and incubated with an transfected cells with Cy3-SS/AS-3N3 EGFP siRNA and NP-45 as
equal molar ratio of TAT47-57 peptide at room temperature for 1 hr. described above. Cells were incubated in transfection mixture for
A cysteine residue added to the amino terminus of TAT47-57 peptide 6 hr and washed three times with PBS (Invitrogen) to remove the
or TAT47-57-derived oligocarbamate was used for siRNA conjugation. transfection mixture. Total DNA, RNA, and the transfected Cy3-SS/
The reaction was then quenched by addition of reaction buffer con- AS-3N3 EGFP siRNA were isolated from the cells and subjected to
taining 50 mM cysteine. TAT47-57 peptide conjugates were analyzed fluorescence measurements on the PTI fluorescence spectropho-
and purified by 20% nondenaturing polyacrylamide gel electropho- tometer as described above.
resis. siRNA conjugated to TAT47-57 peptide and carbamate exhibited
retarded mobility when compared to unmodified duplex siRNA. Silencing of CDK9 Expression by siRNA Delivered
by TAT47-57 Peptide and Nanoparticles
To test the effect of siRNA delivered by cell penetrating TAT47-57Cellular Uptake Analysis of siRNAs Conjugated
with TAT47-57 Peptide peptide, SS/AS-3TAT47-57 or SS/AS-3TAT47-57 (carbamate), or NP-
45, CDK9 siRNAs were added into the medium of cultured HeLa21 nt 5 Cy3-labeled EGFP sense strand siRNA was deprotected,
annealed to 3N3 modified antisense strand siRNA, purified, and cells. For control experiments, 150 nM SS/AS-3N3 CDK9 siRNA
was transfected into HeLa cells using Lipofectamine as describedthen conjugated to TAT47-57 peptide with or without oligocarbamate
modification as described above. HeLa cells were plated on 60 mm above. At 42 hr posttransfection, cells lysates were prepared and
quantified as described above. Protein in 60 g of total cell lysateplates 16 hr before transfection at 70% confluency. Various amounts
of Cy3-SS/AS-3TAT47-57 or Cy3-SS/AS-3TAT47-57 (carbamate) EGFP was resolved by 10% SDS-PAGE, transferred onto a polyvinylidene
difluoride membrane (PVDF membrane, Bio-Rad), and probed withsiRNAs were added to the medium and cells were incubated with
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antibodies against CDK9 (Santa Cruz). As a loading control, the 13. Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A sys-
tem for stable expression of short interfering RNAs in mamma-same membrane was also blotted with anti-hCycT1 antibody (Santa
Cruz). Protein was visualized with BM Chemiluminescence Blotting lian cells. Science 296, 550–553.
14. Qin, X.F., An, D.S., Chen, I.S., and Baltimore, D. (2003). InhibitingKit (Roche Molecular Biochemicals). Blots were exposed to X-ray
film (Kodak MR-1) for various times (between 30 s and 5 min). HIV-1 infection in human T cells by lentiviral-mediated delivery
of small interfering RNA against CCR5. Proc. Natl. Acad. Sci.
USA 100, 183–188.siRNA Localization Studies
15. Shen, C., Buck, A.K., Liu, X., Winkler, M., and Reske, S.N. (2003).HeLa cells were cultured in 35 mm dishes having glass cover slip
Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539,bottoms (MatTek Corporation, Ashland, MA). SS/AS-3TAT47-57 or
111–114.SS/AS-3TAT47-57 (carbamate), or NP-45, EGFP siRNAs were added
16. Stewart, S.A., Dykxhoorn, D.M., Palliser, D., Mizuno, H., Yu, E.Y.,into the medium of cultured HeLa cells. For control experiments,
An, D.S., Sabatini, D.M., Chen, I.S., Hahn, W.C., Sharp, P.A., etsiRNA was transfected into HeLa cells using Lipofectamine as de-
al. (2003). Lentivirus-delivered stable gene silencing by RNAi inscribed above. At 16 hr posttreatment, the Cy3 signal of the siRNAs
primary cells. RNA 9, 493–501.in living cells was monitored by Leica confocal imaging spectropho-
17. Ohki, E.C., Tilkins, M.L., Ciccarone, V.C., and Price, P.J. (2001).tometer system (TCS-SP2) attached to a Leica DMIRE inverted fluo-
Improving the transfection efficiency of post-mitotic neurons.rescence microscope and equipped with an argon laser, two HeNe
J. Neurosci. Methods 112, 95–99.lasers, an acousto-optic tunable filter (AOTF) to attenuate individual
18. Lindgren, M., Hallbrink, M., Prochiantz, A., and Langel, U. (2000).visible laser lines, and a tunable acousto-optical beam splitter
Cell-penetrating peptides. Trends Pharmacol. Sci. 21, 99–103.(AOBS). A 63, 1.32 NA oil immersion objective was employed. In
19. Schwarze, S.R., and Dowdy, S.F. (2000). In vivo protein trans-addition, at 16 hr posttreatment, cells were fixed in 100% methanol
duction: intracellular delivery of biologically active proteins,at 20C for 10 min and then subjected to DAPI staining, which
compounds and DNA. Trends Pharmacol. Sci. 21, 45–48.was performed by adding one drop of the Vectashield mounting
20. Prochiantz, A. (2000). Messenger proteins: homeoproteins, TATmedium with DAPI (VECTOR) on the cells.
and others. Curr. Opin. Cell Biol. 12, 400–406.
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